Previous 10 | Next 10 |
home / stock / mrvl:cc / mrvl:cc news
Calgary, Alberta--(Newsfile Corp. - January 6, 2023) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the " Company " or " Marvel "), are pleased to announce that it has successfully completed a multi-kilogram scale run u...
Calgary, Alberta--(Newsfile Corp. - January 3, 2023) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the " Company " or " Marvel "), is pleased to announce that it has successfully completed its dose-ranging toxicology stu...
Calgary, Alberta--(Newsfile Corp. - December 23, 2022) - Marvel Biosciences Inc. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the " Company " or " Marvel "), is pleased to announce that it has entered into a Letter Agreement for Market Stabilization an...
Calgary, Alberta--(Newsfile Corp. - December 20, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the " Company " or " Marvel "), today announced that its board of directors has approved the grant of incentive stock o...
Calgary, Alberta--(Newsfile Corp. - December 12, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the " Company " or " Marvel "), announces it has initiated its 10-day, dose-ranging toxicology study, using dogs, for i...
Calgary, Alberta--(Newsfile Corp. - December 7, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the " Company " or " Marvel "), is pleased to announce that it has initiated its 7-day dose-ranging, toxicology study, u...
Calgary, Alberta--(Newsfile Corp. - November 24, 2022) - Marvel Biosciences Inc. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the " Company " or " Marvel "), is pleased to announce that, effective November 23, 2022, Mr. Babak Pedram has joined its Boa...
A Calgary-based %Biotech company is turning heads on Tuesday after it was announced that a recent study showed its lead drug candidate MB-204 demonstrated a 400% increase in the survival rate of animals being treated by high doses of chemotherapy treatment, cis-platinum, according to th...
Calgary, Alberta--(Newsfile Corp. - November 22, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the " Company " or " Marvel "), is pleased to announce that in a recent study done by the Company, its lead drug can...
Palm Beach, FL – November 14, 2022 – FinancialNewsMedia.com News Commentary – Anti-anxiety drugs are medications that are used to treat anxiety disorders that are mainly used to relieve anxiety and tension, work by reducing the symptoms of anxiety, such as f...
News, Short Squeeze, Breakout and More Instantly...
Marvel Biosciences Corp. Company Name:
MRVL:CC Stock Symbol:
TSXVC Market:
Marvel Biosciences Corp. Website:
Calgary, Alberta--(Newsfile Corp. - July 24, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), today is pleased to announce the extension of its collaboration with Drs. Julie Le Me...
Calgary, Alberta--(Newsfile Corp. - July 19, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the " Company " or " Marvel "), is pleased to report that, further to its press releases of May 16, 2024 and June 21, 2024, it has ...
Calgary, Alberta--(Newsfile Corp. - July 9, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to highlight the recently published paper "Neuronal A2A receptor exacerbate...